Predicted protein targets (top 11)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | FAP | Q12884 | 5/20 | 0.46 |
| ▸ | MAP1LC3B | Q9GZQ8 | 2/20 | 0.38 |
| ▸ | SIRT5 | Q9NXA8 | 1/20 | 0.36 |
| ▸ | SIRT2 | Q8IXJ6 | 8/20 | 0.36 |
| ▸ | SIRT1 | Q96EB6 | 7/20 | 0.36 |
| ▸ | SIRT3 | Q9NTG7 | 3/20 | 0.36 |
| ▸ | NPY1R | P25929 | 1/20 | 0.35 |
| ▸ | NPY2R | P49146 | 1/20 | 0.35 |
| ▸ | NPY4R | P50391 | 1/20 | 0.35 |
| ▸ | NPY5R | Q15761 | 1/20 | 0.35 |
| ▸ | FURIN | P09958 | 1/20 | 0.35 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL18823482 | 1.00 | FAP (0.46) | FAPMAP1LC3BSIRT5SIRT2SIRT1 | |
| SCHEMBL19387405 | 1.00 | FAP (0.46) | FAPMAP1LC3BSIRT5SIRT2SIRT1 | |
| SCHEMBL23268956 | 0.99 | FAP (0.47) | FAPMAP1LC3BSIRT5SIRT2SIRT1 | |
| SCHEMBL18823198 | 0.99 | FAP (0.47) | FAPMAP1LC3BSIRT5SIRT2SIRT1 | |
| SCHEMBL18823197 | 0.99 | FAP (0.47) | FAPMAP1LC3BSIRT5SIRT2SIRT1 | |
| SCHEMBL24068331 | 0.99 | FAP (0.47) | FAPMAP1LC3BSIRT5SIRT2SIRT1 | |
| SCHEMBL18909001 | 0.99 | FAP (0.47) | FAPMAP1LC3BSIRT5SIRT2SIRT1 | |
| SCHEMBL19708797 | 0.99 | FAP (0.47) | FAPMAP1LC3BSIRT5SIRT2SIRT1 | |
| SCHEMBL20340686 | 0.97 | FAP (0.46) | FAPMAP1LC3BSIRT5SIRT2SIRT1 | |
| SCHEMBL18908999 | 0.96 | FAP (0.43) | FAPMAP1LC3BSIRT5SIRT2SIRT1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 8 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20230183326-A1 | PROTEIN-POLYMER-DRUG CONJUGATES | ASANA BIOSCIENCES, LLC | 2023-06-15 | — | — | US | disclosed |
| US-20230021500-A1 | CYSTEINE ENGINEERED ANTIBODY-DRUG CONJUGATES WITH PEPTIDE-CONTAINING LINKERS | MERSANA THERAPEUTICS, INC. | 2023-01-26 | — | — | US | disclosed |
| US-11135307-B2 | Peptide-containing linkers for antibody-drug conjugates | MERSANA THERAPEUTICS, INC. (US) | 2021-10-05 | — | — | US | disclosed |
| US-10772971-B2 | Methods of producing drug-carrying polymer scaffolds and protein-polymer-drug conjugates | Mersana Therpeutics, Inc. (US) | 2020-09-15 | — | — | US | disclosed |
| US-20190241649-A1 | PROTEIN-POLYMER-DRUG CONJUGATES | MERSANA THERAPEUTICS, INC. | 2019-08-08 | — | — | US | disclosed |
| US-20180154018-A1 | PEPTIDE-CONTAINING LINKERS FOR ANTIBODY-DRUG CONJUGATES | MERSANA THERAPEUTICS, INC. | 2018-06-07 | — | — | US | disclosed |
| US-20180140716-A1 | PROTEIN-POLYMER-DRUG CONJUGATES | MERSANA THERAPEUTICS, INC. | 2018-05-24 | — | — | US | disclosed |
| US-9849191-B2 | Protein-polymer-drug conjugates | MERSANA THERAPEUTICS, INC. (US) | 2017-12-26 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (7 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20190241649-A1 | PROTEIN-POLYMER-DRUG CONJUGATES | PBRM1, STAMBP, TSPO | FAP 1855/4885MAP1LC3B 194/4885SIRT5 2313/4885 |
| US-11135307-B2 | Peptide-containing linkers for antibody-drug conjugates | CD2BP2, DNPEP, LNPEP | FAP 336/4885MAP1LC3B 1163/4885SIRT5 3290/4885 |
| US-20230183326-A1 | PROTEIN-POLYMER-DRUG CONJUGATES | PBRM1, STAMBP, TSPO | FAP 1855/4885MAP1LC3B 194/4885SIRT5 2313/4885 |
| US-20180140716-A1 | PROTEIN-POLYMER-DRUG CONJUGATES | PBRM1, STAMBP, TSPO | FAP 1855/4885MAP1LC3B 194/4885SIRT5 2313/4885 |
| US-10772971-B2 | Methods of producing drug-carrying polymer scaffolds and protein-polymer-drug conjugates | PBRM1, BRAP, STAMBP | FAP 1957/4885MAP1LC3B 979/4885SIRT5 2789/4885 |
| US-20230021500-A1 | CYSTEINE ENGINEERED ANTIBODY-DRUG CONJUGATES WITH PEPTIDE-CONTAINING LINKERS | LNPEP, DNPEP, QPCT | FAP 869/4885MAP1LC3B 1994/4885SIRT5 2669/4885 |
| US-20180154018-A1 | PEPTIDE-CONTAINING LINKERS FOR ANTIBODY-DRUG CONJUGATES | CD2BP2, DNPEP, LNPEP | FAP 336/4885MAP1LC3B 1163/4885SIRT5 3290/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.